

Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	To Be Assigned
				Filing Date	Herewith
				First Named Inventor	Huy ONG et al.
				An Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	20747/240 (ARDCK/P32478US)

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴	Kind Code ² (if known)				
/S.M./	1	WO	00/23097	04/27/2000	Sahltech I Göteborg AB		
	2	WO	98/22124	05/28/1998	Pharmacia & Upjohn AB		
	3	WO	00/67770	11/16/2000	Sahltech I Göteborg AB		
	4	WO	00/09537	02/24/2000	Administrators of the Tulane Educational Fund		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ³
/S.M./	5	Broglio et al., "Effects of Acute Hexarelin Administration on Cardiac Performance in Patients with Coronary Artery Disease During By-Pass Surgery," <i>European Journal of Pharmacology</i> 448(2-3):193-200 (2002)		
	6	Walker et al., "Effects of Stimulated Growth Hormone Secretion on Age-Related Changes in Plasma Cholesterol and Hepatic Low Density Lipoprotein Messenger RNA Concentrations," <i>Mechanisms of Ageing and Development</i> 75(3):215-226 (1994)		
	7	Marleau et al., "Effect of Growth Hormone Releasing Peptides (GHRPs) on Monocyte/Macrophage Scavenger Receptors (SR) B (CD36) Expression and Monocyte Trafficking," <i>Inflammation Research</i> 50(SUPP 3):S154 (2001)		
	8	Bodart et al., "CD35 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart," <i>Circulation Research</i> 90(8):844-849 (2002)		

Examiner Signature	/Stacey Macfarlane/	Date Considered	09/13/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.